Cancer still poses a significant challenge in healthcare since traditional treatments often fail to produce desired results and patient outcomes. Conventional therapies, like chemotherapy and radiation, can have substantial side effects and may not always be able to eliminate cancer cells. Moreover, the heterogeneity of tumors and individual responses to treatment create barriers to achieving consistent and long-lasting outcomes.

Critical Developments in Cancer Immunotherapy offers a compelling solution to these challenges by delving into the cutting-edge field of cancer immunotherapy. This book provides a comprehensive guide to the latest advancements in harnessing the body's immune system to fight cancer. Focusing on critical strategies like checkpoint inhibitors and CAR T-cell therapy, the book provides insights into novel approaches that offer greater precision and effectiveness in cancer treatment.

Ideal for a diverse audience, including students, researchers, and healthcare professionals, this book bridges complex scientific concepts with accessible language. It aims to enhance understanding of how the immune system can be leveraged to combat cancer. More importantly, it serves as a catalyst for further innovation and application in this dynamic field. Critical Developments in Cancer Immunotherapy is not just a book; it is a beacon of hope and knowledge, illuminating the path to more effective and personalized cancer treatments.

Coverage:

The many academic areas covered in this publication include, but are not limited to:

Adoptive Cell Therapies
Bispecific T-Cell Engagers (BiTEs)
Cancer Immunotherapy
CAR T Cells
Dendritic Cells
Immune Checkpoint Blockade
Macrophage Polarization
Monoclonal Antibody Therapies
Myeloid-Derived Suppressor Cells (MDSCs)
Natural Killer (NK) Cells
Oncolytic Viruses
Regulatory T Cells (Tregs)
Therapeutic Vaccines

Table of Contents

Search this Book:

Reset

Editor/Author Biographies

Dr. Mohsen Sheykhhasan currently serves at the Department of Mesenchymal Stem Cell, the Academic Center for Education, Culture and Research in Iran, Qom. He studied at Mazandaran University, in Iran, where he obtained a master’s degree in Biotechnology in 2010. After years of working in the Stem Cell field in Department of Mesenchymal Stem Cell, the Academic Center for Education, Culture and Research, he obtained a Ph.D’s degree in Medical Biotechnology from Hamadan University of Medical Sciences, Hamadan, Iran in 2022. He is interested in fields including immunotherapy, CAR T cell, Dendritic cell, stem cells, exosomes, and non-coding RNA.

Piao Yang, an esteemed figure in the realm of Biological Sciences, has achieved notable academic and professional milestones. Educational Background: Yang's academic journey culminated in earning the highest degree of Ph.D. in Plant Pathology, awarded by The Ohio State University, a prestigious university known for its rigorous academic standards and contributions to research in the field. Current Position and Affiliation: As of now, Dr. Yang holds the position of postdoc fellow in the Department of Molecular Genetics at the College of Arts and Sciences, The Ohio State University. This role signifies a significant milestone in Dr. Yang's career, reflecting a deep commitment to academic excellence and research in molecular genetics. Academic Contributions: Over the years, Dr. Yang's academic journey has been marked by a series of significant contributions to the field of Biological Sciences. These include publication of 17 peer-reviewed articles and 1 book chapter. Dr. Yang's work has not only advanced the understanding of plant-microbe interactions but also opened new avenues for further research and exploration in molecular genetics. The impact of these contributions is evident in the numerous citations and recognitions received from the academic community. Dr. Yang's dedication to research and academia continues to inspire and influence both peers and students in the field, contributing significantly to the advancement of molecular genetics and related areas of study.

Dr. Poondla is a distinguished scholar and author with a deep commitment to advancing knowledge in genome editing. Holding a Ph.D. in Cancer Biology from the Institute of Biomedical Science & Engineering, Hanyang University, Seoul, South Korea in the year 2019 where he worked cervical cancer using CRISPR/Cas9 genome editing Dr. Poondla has dedicated their academic career to rigorous research and scholarly pursuits. Currently, Dr. Poondla holds the position of Sr. Research Associate at Icahn School of Mount Sinai, New York, US. In this role, they investigating the molecular and cellular mechanisms underlying stroke development and biological processes involved in neural recovery post stroke. Throughout their academic journey, Dr. Poondla has been a prolific contributor to the field, with a focus on cervical cancer and immunology of HIV. Their research has been widely published in reputable journals such as Molecular Therapy and they have presented their findings at numerous national and international conferences. With a passion for gene therapy, Dr. Poondla's work has garnered recognition for its innovative approach and significant impact on the academic community. Their expertise extends to [mention any additional areas of specialization], making them a sought-after authority in precision medicine field. In addition to their scholarly pursuits, Dr. Poondla is dedicated to mentoring the next generation of immunology professionals. They have supervised numerous graduate students, fostering a collaborative and intellectually stimulating environment. This book, Immunotherapy of Cancer is a culmination of Dr. Poondla's years of research, expertise, and dedication to advancing knowledge in the field. It is a testament to their commitment to sharing insights and contributing to the ongoing dialogue within the academic community.

Archiving

All of IGI Global's content is archived via the CLOCKSS and LOCKSS initiative. Additionally, all IGI Global published content is available in IGI Global's InfoSci^® platform.